Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 21 12 2022
accepted: 03 03 2023
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 22 3 2023
Statut: epublish

Résumé

No biomarkers have been identified in bronchoalveolar lavage fluid (BALF) for predicting fibrosis progression or prognosis in progressive fibrosing interstitial lung disease (PF-ILD). We investigated BALF biomarkers for PF-ILD diagnosis and prognosis assessment. Overall, 120 patients with interstitial pneumonia who could be diagnosed with PF-ILD or non PF-ILD were enrolled in this retrospective study. PF-ILD was diagnosed according to Cottin's definition. All patients underwent bronchoscopy and BALF collection. We evaluated blood and BALF parameters, high-resolution computed tomography (HRCT) patterns, and spirometry data to identify factors influencing PF-ILD diagnosis and prognosis. On univariate logistic analysis, age, sex, the BALF white blood cell fraction (neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio), BALF flow cytometric analysis (CD8), and an idiopathic pulmonary fibrosis/usual interstitial pneumonia pattern on HRCT were correlated with PF-ILD diagnosis. Multivariate logistic regression analysis revealed that sex (male), age (cut-off 62 years, area under the curve [AUC] 0.67; sensitivity 0.80; specificity 0.47), white blood cell fraction in BALF (NLR, neutrophil, and lymphocyte), and CD8 in BALF (cut-off 34.2; AUC 0.66; sensitivity, 0.74; specificity, 0.62) were independent diagnostic predictors for PF-ILD. In BALF, the NLR (cut-off 8.70, AUC 0.62; sensitivity 0.62; specificity 0.70), neutrophil count (cut-off 3.0, AUC 0.59; sensitivity 0.57; specificity 0.63), and lymphocyte count (cut-off 42.0, AUC 0.63; sensitivity 0.77; specificity 0.53) were independent diagnostic predictors. In PF-ILD patients (n = 77), lactate dehydrogenase (cut-off 275, AUC 0.69; sensitivity 0.57; specificity 0.78), Krebs von den Lungen-6 (cut-off 1,140, AUC 0.74; sensitivity 0.71; specificity 0.76), baseline forced vital capacity (FVC) (cut-off 1.75 L, AUC 0.71; sensitivity, 0.93; specificity, 0.46), and BALF neutrophil ratio (cut-off 6.0, AUC 0.72; sensitivity 0.79; specificity 0.80) correlated with death within 3 years. The BALF cellular ratio, particularly the neutrophil ratio, correlated with the diagnosis and prognosis of PF-ILD. These findings may be useful in the management of patients with interstitial pneumonia.

Identifiants

pubmed: 36930615
doi: 10.1371/journal.pone.0283288
pii: PONE-D-22-34942
pmc: PMC10022771
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0283288

Informations de copyright

Copyright: © 2023 Watase et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur Respir Rev. 2019 Feb 27;28(151):
pubmed: 30814139
Respirology. 2009 Sep;14(7):934-9
pubmed: 19740255
BMC Pulm Med. 2017 Apr 20;17(1):67
pubmed: 28427425
PLoS One. 2018 Feb 5;13(2):e0190189
pubmed: 29401501
Respir Res. 2005 Jul 24;6:81
pubmed: 16042790
Eur J Clin Invest. 2019 Jan;49(1):e13037
pubmed: 30316204
Lancet Respir Med. 2020 Sep;8(9):925-934
pubmed: 32890499
Eur Respir J. 2018 May 17;51(5):
pubmed: 29773608
Eur Respir J. 2022 Jun 16;59(6):
pubmed: 34737223
Respir Res. 2021 May 24;22(1):162
pubmed: 34030695
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
BMC Med. 2020 Nov 20;18(1):360
pubmed: 33213430
J Immunol. 2015 Dec 1;195(11):5251-60
pubmed: 26519529
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):503-513
pubmed: 29629626
Stroke. 2021 Mar;52(3):859-867
pubmed: 33517702
BMC Pulm Med. 2018 May 2;18(1):65
pubmed: 29720140
J Leukoc Biol. 2015 Aug;98(2):143-52
pubmed: 25743626
Clin Appl Thromb Hemost. 2016 Jul;22(5):405-11
pubmed: 25667237
Chest. 2008 Jan;133(1):226-32
pubmed: 18071016
Am J Emerg Med. 2020 Mar;38(3):641-647
pubmed: 31785981
Respir Med. 2021 Sep;186:106534
pubmed: 34260978
J Diabetes Res. 2020 Apr 28;2020:6219545
pubmed: 32405503
Minerva Med. 2022 Jun;113(3):526-531
pubmed: 32407050
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Ann Allergy Asthma Immunol. 2019 Mar;122(3):337-339.e1
pubmed: 30508585
Respir Med. 2014 May;108(5):793-9
pubmed: 24636811
Eur Respir J. 2020 Jun 25;55(6):
pubmed: 32217654
Sci Rep. 2021 Aug 13;11(1):16481
pubmed: 34389774

Auteurs

Mayuko Watase (M)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Takao Mochimaru (T)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Department of Allergy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Honomi Kawase (H)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Hiroyuki Shinohara (H)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Shinobu Sagawa (S)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Toshiki Ikeda (T)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Shota Yagi (S)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Hiroyuki Yamamura (H)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Emiko Matsuyama (E)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Masanori Kaji (M)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Momoko Kurihara (M)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Midori Sato (M)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Kohei Horiuchi (K)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Risa Watanabe (R)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Shigenari Nukaga (S)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Kaoru Irisa (K)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Ryosuke Satomi (R)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Yoshitaka Oyamada (Y)

Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Department of Allergy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH